Peter Diamandis
HQ Location: USA
RANK #552
Peter Diamandis is co-founder and board member of Lifeforce Digital. He is also co-founder and vice-chairman of Covaxx. He is chairman of the advisory board of Radicle Science. He is an advisor to Immunis. He is an advisor to Guardian Circle and Republic. He co-founded and serves as managing director and vice chairman of Space Adventures and Human Longevity. He is also a co-founder and general partner of Bold Capital Partners. He is a co-founder and board member of Herox. He is an observer on the board of directors of Virgin Hyperloop. He is a co-founder and advisor to Eleven. He is an advisor to OpenGate Capital. Co-founder and executive chairman of Singularity University. Co-founder and chairman of XPRIZE. Co-founder of Zero-G. Served as executive director at BlastOff! He is also an alumnus of Silicon Valley University, which advises the world's leaders on exponentially emerging technologies. In commercial space, he was co-founder and co-chairman of Planetary Resources, a company developing spacecraft to detect and search for fuel and valuable materials on asteroids. He was a member of the board of directors of Planetary Power. He has served as an advisor to Experfy and Global Ventures (Dubai). He is a member of the board of directors of Form Bio. Serves on the board of directors of Venom. Co-founder and Vice Chairman of Vaxxinity. He holds degrees in molecular genetics and aerospace engineering from MIT and a PhD from Harvard Medical School.
Numbers of Unicorns
2
224
Rank (Xs)
#552
Investments
32
Exits
14
Numbers of Unicorns
2
224
Rank (Xs)
#552
Investments
32
Exits
14
All Unicorns
Logo
Company name
ENTRY ROUND
VALUATION at entry ($M)
VALUATION
Human Longevity
Human Longevity
Series A
$120M
83
$10000M
Magic Leap
Magic Leap
Series B
$1000.01M
2
$2000M
All $100M+
Company name
ENTRY ROUND
VALUATION at entry ($M)
VALUATION
625
Booster
$8.9M
87
$775M
1662
Enlitic
$10M
13
$125M
2366
High Fidelity
Series A
$10M
18
$183.15M
5997
Virgin Hyperloop
Series A1
$33.61M
14
$472.23M
5993
Viome Life Sciences
Series A
$70M
5
$339M
5968
Vicarious
Series B
$220.82M
2
$400M
The information is provided for informational purposes. The company does not bear any responsibility for the published data.